*Po-Yu Chen1,2,3,4, Chih-Chiang Chiu1,2, Chin-Kuo Chang5,6,7, Mong-Liang Lu2,4,9, Cho-Yin Huang1,6, Chun-Hsin Chen2,4,9, Ming-Chyi Huang1,2,4,8
(1. Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan, 2. Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 3. Department of Psychology, National Chengchi University, Taipei, Taiwan, 4. Psychiatric Research Center, Wang-Fang Hospital, Taipei Medical University, Taipei, Taiwan, 5. Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan, 6. Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 7. Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK, 8. Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan, 9. Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan)
キーワード:Orexin-A, Clozapine, Treatment-resistant schizophrenia, Treatment response, Cognition
抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。